2. Signaling Pathways
  3. Immunology/Inflammation
  4. FLAP

FLAP

5-lipoxygenase-activating protein; 5-LO activating protein

FLAP

Related Products

PDF 0.19 MB

FLAP (Arachidonate 5-lipoxygenase-activating protein) is an integral membrane protein, which facilitates the transfer of the substrate arachidonic acid (AA) to 5-lipoxygenase (5-LO) to produce leukotrienes (LTs), and is shown to be indispensable for cellular LT biosynthesis. FLAP transfers arachidonic acid to 5-LOX protein, thereby enabling this enzyme to efficiently produce oxidized lipid products (mainly eicosanoids) that are important in cell growth, differentiation and death particularly apoptosis.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-136484
    FEN1-IN-3
    		Inhibitor 98.06%
    FEN1-IN-3 (Compound 4) is a human flap endonuclease-1 (hFEN1) inhibitor. FEN1-IN-3 stabilizes hFEN1 with an EC50 of 6.8 μM.
    FEN1-IN-3
  • HY-14163
    AM103
    		Inhibitor 99.26%
    AM 103 is a potent and selective FLAP inhibitor, with an IC50 value of 4.2 nM.
    AM103
  • HY-12995A
    (S)-BI 665915
    		Inhibitor
    (S)-BI 665915 is an orally active oxadiazole-containing 5-lipoxygenase-activating protein (FLAP) inhibitor with an IC50 of 1.7 nM for FLAP binding. (S)-BI 665915 inhibits FLAP functional in human whole blood with an IC50 of 45 nM. (S)-BI 665915 demonstrates an excellent cross-species agent metabolism and pharmacokinetics (DMPK) profile and a dose-dependent inhibition of LTB4 production.
    (S)-BI 665915
  • HY-14166A
    MK-886 sodium salt
    		Inhibitor
    MK-886 (L 663536) sodium salt is a potent, cell-permeable and orally active FLAP (IC50 of 30 nM) and leukotriene biosynthesis (IC50s of 3 nM and 1.1 μM in intact leukocytes and human whole blood, respectively) inhibitor. MK-886 sodium salt is also a non-competitive PPARα antagonist and can induce apoptosis.
    MK-886 sodium salt
  • HY-139678
    SC13
    		Inhibitor
    SC13 is an orally active, selective Flap structure-specific endonuclease 1 (FEN1) inhibitor and mu opioid receptor (MOR) activator. SC13 impairs DNA damage repair and induces apoptosis in cancer cells. SC13 activates cGAS-STING signaling, increases chemokine secretion, and promotes CAR-T cell infiltration at solid tumour sites. SC13 can be used for the research of solid tumours and pain.
    SC13
  • HY-12995
    BI 665915
    		Inhibitor
    BI 665915, a chemical probe, is an orally active and potent 5-lipoxygenase-activating protein (FLAP) inhibitor. BI 665915 inhibits FLAP production that blocks LTB4 biosynthesis in mice. BI 665915 is promising for research of various inflammatory diseases, including respiratory and cardiovascular diseases.
    BI 665915
  • HY-179441
    sEH/FLAP-IN-2
    		Inhibitor
    sEH/FLAP-IN-2 is a selective sEH (IC50 = 12.6 nM)/FLAP dual inhibitor. sEH/FLAP-IN-2 highlights the reduction of 5-LOX/FLAP- and sEH-derived LMs, resulting in a favourable redistribution of LMs. sEH/FLAP-IN-2 can be used for the study of peritonitis.
    sEH/FLAP-IN-2
  • HY-156329
    sEH/FLAP-IN-1
    		Inhibitor
    sEH/FLAP-IN-1 (Compound 46A) is a sEH/FLAP inhibitor. sEH/FLAP-IN-1 inhibits 5-LOX product formation in SACM-stimulated PBMCs (EC50: 11 nM). sEH/FLAP-IN-1 inhibit sEH (EC50: 18 nM) and thromboxane production. sEH/FLAP-IN-1 can be used for research of inflammatory diseases.
    sEH/FLAP-IN-1
  • HY-118197
    L-669083
    		Inhibitor
    L-669083 is a leukotriene biosynthesis inhibitor whose structure is based on a mixture of indole and quinoline. In this study, a potent radioiodinated photoaffinity analog of L-689,037, [125I] L-691,678, was developed and characterized for immunoprecipitation studies showing that the quindole series of leukotriene biosynthesis inhibitors directly interact with FLAP. In addition, the results showed that MK-886, L-674,573, and L-689,037 competed with [125I] L-691,678 and [125I] L-669083 for binding to FLAP in a concentration-dependent manner, indicating that these three leukotriene biosynthesis inhibitors share a binding site on FLAP, further demonstrating that FLAP is a suitable target for structurally diverse leukotriene biosynthesis inhibitors.
    L-669083
  • HY-118506
    BRP-7
    		Inhibitor
    BRP-7 is a 5-lipoxygenase activating protein (FLAP) inhibitor with an IC50 of 0.31 μM. BRP-7 inhibits the co-localization of 5-lipoxygenase (5-LOX) and FLAP by targeting FLAP, thereby blocking the transfer of arachidonic acid (AA) to 5-LOX and suppressing the production of leukotrienes (LTs) (IC₅₀ = 0.15 μM). BRP-7 does not inhibit cyclooxygenase (COX-1/COX-2) or microsomal prostaglandin E₂ synthase-1 (mPGES-1), and does not affect cell viability or AA release. BRP-7 exhibits significant anti-inflammatory effects in rat pleurisy and mouse peritonitis models. BRP-7 can be used for the study of inflammatory diseases.
    BRP-7
  • HY-12996
    AZD6642
    		Inhibitor
    AZD6642 is a 5-lipoxygenase activating protein (FLAP) inhibitor. AZD6642 can effectively inhibit the production of LTB4. AZD6642 exhibits high oral bioavailability in rats and dogs. AZD6642 can be used in the research of inflammatory diseases.
    AZD6642
  • HY-155204
    LTB4-IN-2
    LTB4-IN-2 (Comopund 6x) is a Leukotriene B4 (LTB4) inhibitor. LTB4-IN-2 inhibits Leukotriene B4 formation (IC50: 1.15 μM) by selectively targeting 5-Lipoxygenase-activating protein (FLAP). LTB4-IN-2 can be used for anti-inflammatory research.
    LTB4-IN-2
  • HY-50714R
    Quiflapon sodium (Standard)
    		Inhibitor
    Quiflapon (sodium) (Standard) is the analytical standard of Quiflapon (sodium). This product is intended for research and analytical applications. Quiflapon sodium (MK-591 sodium) is a selective and specific 5-Lipoxygenase-activating protein (FLAP) inhibitor. Quiflapon sodium is an orally active Leukotriene biosynthesis inhibitor. Induces apoptosis.
    Quiflapon sodium (Standard)
  • HY-14162
    AM103 free acid
    		Inhibitor
    AM103 (free acid) is a selective FLAP inhibitor that can block the first step of the LT pathway, which is 5-LO activation. AM103 (free acid) can inhibit the production of LTB4 and cysteinyl leukotrienes (CysLT). AM103 (free acid) has anti-inflammatory activity in a mouse model of chronic lung inflammation and can extend the survival time of mice injected with platelet-activating factor. AM103 (free acid) can be used for research on respiratory diseases such as asthma.
    AM103 free acid
  • HY-10037R
    Quiflapon (Standard)
    		Inhibitor
    Quiflapon (Standard) is the analytical standard of Quiflapon. This product is intended for research and analytical applications. Quiflapon (MK-591) is a selective and specific 5-lipoxygenase-activating protein (FLAP) inhibitor with an IC50?of 1.6 nM in a FLAP binding assay. Quiflapon is also a potent and orally active?Leukotriene biosynthesis (LT)?inhibitor, shows IC50?values of 3.1 and 6.1 nM in intact human and elicited rat PMNLs, respectively. Quiflapon induces cell apoptosis.
    Quiflapon (Standard)
  • HY-14166R
    MK-886 (Standard)
    		Inhibitor
    MK-886 (Standard) is the analytical standard of MK-886. This product is intended for research and analytical applications. MK-886 (L 663536) is a potent, cell-permeable and orally active FLAP (IC50 of 30 nM) and leukotriene biosynthesis (IC50s of 3 nM and 1.1 μM in intact leukocytes and human whole blood, respectively) inhibitor. MK-886 is also a non-competitive PPARα antagonist and can induce apoptosis.
    MK-886 (Standard)
  • HY-155407
    ALR-6
    		Antagonist
    ALR-6 is an antagonist of the 5-lipoxygenase (5-LOX) activating protein FLAP and has anti-inflammatory activity. ALR-6 potently inhibits 5-LOX product formation (>80%) in pro-inflammatory M1-MDM and has no significant effect on direct inhibition of 5-LOX.
    ALR-6
  • HY-156194
    FLAP-IN-1
    		Inhibitor
    FLAP-IN-1 (Intermediate 14) is a 5-lipoxygenase-activating protein (FLAP) inhibitor with an IC50 value of 654 nM. FLAP-IN-1 can be used in cardiovascular disease research.
    FLAP-IN-1
  • HY-175883
    FEN1-IN-8
    		Inhibitor
    FEN1-IN-8 (compund 15) is a selective FEN1 inhibitor, with IC50 values of < 100 nM for FEN1 and 100 nM to 1 μM for EXO1, respectively. FEN1-IN-8 can be used for study of colorectal cancer and gastric cancer.
    FEN1-IN-8
  • HY-155408
    ALR-27
    		Antagonist
    ALR-27 is an antagonist of the 5-lipoxygenase (5-LOX) activating protein FLAP and has anti-inflammatory activity. ALR-27 potently inhibits 5-LOX product formation (>80%) in pro-inflammatory M1-MDM, with no significant direct inhibition of 5-LOX. ALR-27 not only reduces prostaglandin and leukotriene (LT) production in neutrophils but also increases the production of specialized prolytic mediators in specific human macrophage phenotypes.
    ALR-27
Cat. No. Product Name / Synonyms Application Reactivity